Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study.

导出 OA

翻译打印收藏纠错

第一作者： Akihiko,Asahina

第一单位： Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.

作者： Akihiko,Asahina ^[1] ; Yukari,Okubo ^[2] ; Akimichi,Morita ^[3] ; Yayoi,Tada ^[4] ; Atsuyuki,Igarashi ^[5] ; Richard G,Langley ^[6] ; Delphine,Deherder ^[7] ; Mizuho,Matano ^[8] ; Veerle,Vanvoorden ^[7] ; Maggie,Wang ^[9] ; Mamitaro,Ohtsuki ^[10] ; Hidemi,Nakagawa ^[1]

作者单位： Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan. ^[1] Department of Dermatology, Tokyo Medical University, Tokyo, Japan. ^[2] Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. ^[3] Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan. ^[4] Department of Dermatology, NTT Medical Center Tokyo, Tokyo, Japan. ^[5] Division of Clinical Dermatology and Cutaneous Science, Department of Medicine, Dalhousie University, Halifax, NS, Canada. ^[6] UCB Pharma, Braine L'alleud, Belgium. ^[7] UCB Pharma, UCB Japan Co., Ltd, 8-17-1 Nishi-Shinjuku, Shinjuku-Ku, Tokyo, 160-0023, Japan. Mizuho.Matano@ucb.com. ^[8] UCB Pharma, Raleigh, NC, USA. ^[9] Department of Dermatology, Jichi Medical University, Tochigi, Japan. ^[10]

关键词 Absolute PASI Active control Bimekizumab Japan subpopulation Plaque psoriasis Randomized controlled trial Ustekinumab

DOI 10.1007/s13555-022-00883-y

PMID 36648594

发布时间 2023-04-10

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交